Abstract:Severe fever with thrombocytopenia syndrome virus (SFTSV) is a novel tick-borne viral pathogen that causes severe fever with thrombocytopenia syndrome (SFTS). The disease was initially reported in central and eastern China, then later in Japan and South Korea, with a mortality rate of 13–30%. Currently, no vaccines or effective therapeutics are available for SFTS treatment. In this study, three monoclonal antibodies (mAbs) targeting the SFTSV envelope glycoprotein Gn were obtained using the hybridoma technique. Two mAbs recognized linear epitopes and did not neutralize SFTSV, while the mAb 40C10 can effectively neutralized SFTSV of different genotypes and also the SFTSV-related Guertu virus (GTV) and Heartland virus (HRTV) by targeting a spatial epitope of Gn. Additionally, the mAb 40C10 showed therapeutic effect in mice infected with different genotypes of SFTSV strains against death by preventing the development of lesions and by promoting virus clearance in tissues. The therapeutic effect could still be observed in mice infected with SFTSV which were administered with mAb 40C10 after infection even up to 4 days. These findings enhance our understanding of SFTSV immunogenicity and provide valuable information for designing detection methods and strategies targeting SFTSV antigens. The neutralizing mAb 40C10 possesses the potential to be further developed as a therapeutic monoclonal antibody against SFTSV and SFTSV-related viruses. Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) is a tick-borne pathogen that causes severe illness known as SFTS. This disease has become a major health concern, particularly in China, Japan and South Korea, with a high mortality rate. Regrettably, there are currently no vaccines or effective treatments available for this disease. To address this critical gap, we developed three monoclonal antibodies (mAbs) targeting a specific region of the SFTSV glycoprotein. Among these mAbs, one, named 40C10, exhibited remarkable neutralizing activity against SFTSV as well as related viruses such as HRTV and GTV. It provided complete protection against disease and death in mice even when administered days after viral exposure. These findings are promising and suggest that mAb 40C10 has potential as a therapeutic option against SFTSV. This work is a significant step towards meeting the urgent need for effective treatments for SFTS.

Mast Cell-Derived Proteases Induce Endothelial Permeability and Vascular Damage in Severe Fever with Thrombocytopenia Syndrome

Single-cell landscape of peripheral immune responses to fatal SFTS

Downregulation of Interferon-β and Inhibition of TLR3 Expression are associated with Fatal Outcome of Severe Fever with Thrombocytopenia Syndrome

SFTSV infection is associated with transient overproliferation of monoclonal lambda-type plasma cells

Severe fever with thrombocytopenia syndrome virus induces platelet activation and apoptosis via a reactive oxygen species-dependent pathway

Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome

Severe fever with thrombocytopenia syndrome virus replicates in platelets and enhances platelet activation.

Severe Fever with Thrombocytopenia Syndrome Virus-Induced Macrophage Differentiation is Regulated by Mir-146

The clinical and immunological characteristics in fatal severe fever with thrombocytopenia syndrome virus (SFTSV) infection

Serum lipidome reveals lipid metabolic dysregulation in severe fever with thrombocytopenia syndrome

Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection

Nonmuscle Myosin Heavy Chain IIA is a Critical Factor Contributing to the Efficiency of Early Infection of Severe Fever with Thrombocytopenia Syndrome Virus

SFTSV Infection Induces BAK/BAX-Dependent Mitochondrial DNA Release to Trigger NLRP3 Inflammasome Activation.

Concurrent Measurement of Dynamic Changes in Viral Load, Serum Enzymes, T Cell Subsets, and Cytokines in Patients with Severe Fever with Thrombocytopenia Syndrome

Targeting the neurovascular unit: Development of a new model and consideration for novel strategy for Alzheimer's disease

Correlations between clinical features and death in patients with severe fever with thrombocytopenia syndrome.

MCP-3 as a prognostic biomarker for severe fever with thrombocytopenia syndrome: a longitudinal cytokine profile study

A longitudinal sampling study of transcriptomic and epigenetic profiles in patients with thrombocytopenia syndrome

Antibodies Against Severe Fever with Thrombocytopenia Syndrome Virus in Healthy Persons, China, 2013.

[Statistic rCBF study of extrapyramidal disorders].

Identification and characterization of three monoclonal antibodies targeting the SFTSV glycoprotein and displaying a broad spectrum recognition of SFTSV-related viruses